IL2 and coronary artery disorder: The LILACS (Low-Dose Interleukin-2 in Patients With Stable Ischemic Heart Disease and Acute Coronary Syndromes) study demonstrated significant Treg expansion without adverse events in patients with stable or unstable ischemic heart disease [52].